LGALS3 and Alzheimer disease: Recent findings indicated that the LGALS3/TREM2 signalling pathway, that acts as an inflammatory regulator of amyloid plaque formation, may also be of relevance for AD pathology in humans (Boza-Serrano et al., 2019).